GLP-1 Drugs in Type 1 Diabetes: Off-Label Use, What the Evidence Shows, and the Risks
Why GLP-1 drugs are not approved for T1D
GLP-1 receptor agonists work primarily through insulin-secretion enhancement from pancreatic beta cells, and through glucagon suppression. In type 1 diabetes, the beta cells are absent or destroyed (autoimmune destruction). The insulin-secretion mechanism therefore does not apply.
The FDA approved GLP-1 drugs for type 2 diabetes (where beta cell function, while impaired, is preserved enough to respond to GLP-1 stimulation) and for obesity management (regardless of T2D status). Type 1 diabetes was not studied in the approval trials, and no GLP-1 agonist carries an FDA indication for T1D.
Why off-label use is increasing in T1D
Despite the lack of approval, off-label prescribing of GLP-1 agonists in T1D has grown, primarily driven by:
The obesity-T1D overlap. The prevalence of obesity in adults with T1D has increased substantially as insulin therapy has evolved. Up to 30–40% of adults with T1D in the US now have BMI ≥30. Obesity in T1D worsens insulin resistance, increases insulin requirements, and worsens glycaemic control.
GLP-1 mechanisms that apply in T1D:
- Gastric emptying slowing (reduces post-prandial glucose spikes, independent of beta cell function)
- Central appetite suppression (reduces carbohydrate consumption and overall caloric intake)
- Glucagon suppression (T1D patients still produce glucagon; excess glucagon contributes to hyperglycaemia)
- Weight loss (reduces insulin resistance from adiposity)
These mechanisms are relevant to T1D glycaemic control and weight management even without functional beta cells.
What the evidence shows in T1D
Small RCTs and observational studies:
A meta-analysis of GLP-1 agonist use in T1D (2022, Diabetes Care) synthesised data from 12 trials (n=1,117). Key findings:
- Average HbA1c reduction of approximately 0.4–0.5% from baseline
- Average weight loss of 3–5 kg
- Modest reductions in total daily insulin dose
- No significant increase in hypoglycaemic episodes (a specific concern given the insulin-dependent nature of T1D)
Individual studies showed more variable results. The HbA1c benefit is smaller in T1D than in T2D because the primary insulin-secretion mechanism is absent.
The closed-loop insulin pump context: Several studies have explored GLP-1 agonism specifically in T1D patients using advanced closed-loop insulin delivery systems (artificial pancreas devices). In this context, GLP-1's gastric slowing and glucagon suppression effects may complement automated insulin dosing.
The DKA risk: the most significant safety concern
The primary safety concern in T1D GLP-1 use is diabetic ketoacidosis (DKA), particularly when GLP-1 therapy is combined with SGLT2 inhibitors (another off-label T1D drug class — empagliflozin, dapagliflozin).
The mechanism:
- SGLT2 inhibitors reduce glycosuria threshold and increase ketone body production
- GLP-1 agonists suppress glucagon and may mask signs of impending ketoacidosis
- GLP-1 agonists reduce insulin requirements, and patients or clinicians may reduce insulin — increasing DKA risk
- The combination of SGLT2 + GLP-1 in T1D creates multiple converging DKA risk factors
Clinical evidence: Several case series report DKA in T1D patients on dual SGLT2 + GLP-1 off-label therapy. Euglycaemic DKA (DKA with normal or near-normal blood glucose) is especially concerning because it may not trigger immediate recognition.
Individual GLP-1 monotherapy in T1D (without SGLT2) has not shown a DKA signal in controlled trials, but the concern remains given the theoretical mechanisms.
Practical considerations for T1D patients and prescribers
Who should not use GLP-1 off-label in T1D:
- Patients with prior DKA or DKA-prone history
- Patients already on SGLT2 inhibitors
- Patients with poor glycaemic monitoring adherence
- Patients prone to under-insulinising (skipping doses, dose reduction without guidance)
- Patients with active eating disorders
Precautions if prescribing:
- Do not combine with SGLT2 inhibitors
- Educate about DKA risk and euglycaemic DKA specifically
- Frequent monitoring of ketones, not just glucose
- Insulin dose adjustment should be gradual and monitored
- CGM (continuous glucose monitoring) is essentially mandatory
- Prescribing should be by an endocrinologist familiar with T1D management
What's coming: dedicated T1D trials
The evidence gap may narrow. Several trials are specifically studying GLP-1 agonists in T1D:
PUMA trial (semaglutide in T1D): Phase 2 trial examining semaglutide in adults with T1D and BMI ≥27. Results pending.
Phase 3 pathways: If Phase 2 data is compelling, Novo Nordisk or Eli Lilly could pursue a T1D indication for their respective drugs. This would require dedicated safety and efficacy data, specifically addressing DKA risk.
The autoimmune connection: does GLP-1 affect T1D pathology?
GLP-1 receptors are expressed on pancreatic beta cells. Animal studies have shown GLP-1 agonism can protect beta cells from autoimmune destruction in models of early T1D. Whether this effect is clinically meaningful in humans with established T1D (where most beta cells are already gone) is unclear.
A small number of reports document some residual C-peptide preservation in patients with new-onset T1D treated with GLP-1 agonists, but this research is preliminary and not practice-changing.
Summary
GLP-1 receptor agonists are not FDA-approved for T1D but are used off-label — primarily in adults with T1D and obesity who are not achieving glycaemic targets. Modest benefits in HbA1c reduction (0.4–0.5%) and weight loss (3–5 kg) are documented. The primary safety concern is DKA, particularly when GLP-1 is combined with SGLT2 inhibitors. Off-label prescribing in T1D requires endocrinologist involvement, careful DKA monitoring, and avoidance of SGLT2 co-prescribing.
This article is queued for review by a medical doctor. It should not be used as personal medical advice.